v3.25.4
Segments of Business and Geographic Areas - Income Before Tax by Segment (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Sales to Customers $ 94,193 $ 88,821 $ 85,159
Cost of products sold 30,256 27,471 26,553
Selling, marketing and administrative expenses 23,676 22,869 21,512
Research and development expense 14,665 17,232 15,085
Other (income) expense, net 7,209 (4,694) (6,634)
Earnings before provision for taxes on income 32,581 16,687 15,062
Less: Expense not allocated to segments (6,202) 5,972 7,853
Contingent Consideration 753 1,217  
Abiomed      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Contingent Consideration 400    
Operating Segments      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Sales to Customers 94,193 88,821 85,159
Earnings before provision for taxes on income 26,379 22,659 22,915
Innovative Medicine      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Sales to Customers 60,401 56,964 54,759
Acquisition related costs 400    
Innovative Medicine | Operating Segments      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Sales to Customers 60,401 56,964 54,759
Cost of products sold 15,646 14,036 13,715
Selling, marketing and administrative expenses 11,375 10,906 9,842
Research and development expense 11,827 13,529 11,963
Other (income) expense, net (713) (426) 993
Earnings before provision for taxes on income 22,266 18,919 18,246
MedTech      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Sales to Customers 33,792 31,857 30,400
Acquisition related costs 200 1,000 200
Litigation expense 900 300  
Marketable Security, Realized Gain (Loss) 200    
MedTech | Operating Segments      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Sales to Customers 33,792 31,857 30,400
Cost of products sold 14,549 13,345 12,722
Selling, marketing and administrative expenses 11,354 10,812 10,476
Research and development expense 2,838 3,703 3,122
Other (income) expense, net 938 257 (589)
Earnings before provision for taxes on income $ 4,113 $ 3,740 $ 4,669